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A95 is a chromatin-associated protein that inter-
faces the nuclear envelope (NE) and chromatin. We
report an interaction between HA95 and the inner
nuclear membrane protein lamina-associated polypeptide
 
(LAP) 2
 
 
 
, and a role of this association in initiation of DNA
replication. Precipitation of GST–LAP2
 
 
 
 fusion proteins
and overlays of immobilized HA95 indicate that a ﬁrst
HA95-binding region lies within amino acids 137–242 of
 
LAP2
 
 
 
. A second domain sufﬁcient to bind HA95 colocalizes
with the lamin B–binding domain of LAP2
 
 
 
 at residues
299–373. HA95–LAP2
 
 
 
 interaction is not required for NE
H
 
formation. However, disruption of the association of HA95
 
with the NH
 
2
 
-terminal HA95-binding domain of LAP2
 
 
 
abolishes the initiation, but not elongation, of DNA repli-
cation in puriﬁed G1 phase nuclei incubated in S-phase
extract. Inhibition of replication initiation correlates with
proteasome-mediated proteolysis of Cdc6, a component of
the prereplication complex. Rescue of Cdc6 degradation
with proteasome inhibitors restores replication. We propose
that an interaction of LAP2
 
 
 
, or LAP2 proteins, with HA95
is involved in the control of initiation of DNA replication.
 
Introduction
 
The nuclear envelope (NE)* mediates key nuclear functions
by interacting with chromatin. The inner nuclear membrane
(INM) harbors integral proteins that interact with the nuclear
lamina and chromosomes. Among these, lamina-associated
 
polypeptide (LAP) 2
 
 
 
 binds chromatin in a phosphorylation-
dependent manner (Foisner and Gerace, 1993; Furukawa et
al., 1995) and contains a LAP2, emerin, MAN-1 (LEM)
domain (Lin et al., 2000) that interacts with the DNA-
bridging protein, barrier-to-autointegration factor (BAF)
(Furukawa, 1999). At least six LAP2 isoforms are produced
from alternative mRNA splicing in mammals (Berger et al.,
 
1996). LAP2 proteins share an NH
 
2
 
-terminal 187–amino acid
domain that binds DNA (Cai et al., 2001) and contains the
LEM motif (residues 111–152) (Furukawa, 1999; Shumaker
et al., 2001). LAP2
 
 
 
 also interacts with the germ cell less
(GCL) transcription regulator through residues 219–328
and mediates transcriptional repression alone or together
with GCL (Nili et al., 2001). A lamin B–binding domain
specific for LAP2
 
 
 
 has been identified at residues 299–373
(Furukawa and Kondo, 1998). Injection of LAP2
 
 
 
 fragments
in living cells (Yang et al., 1997) and in vitro studies (Gant et
al., 1999) suggests that LAP2
 
 
 
 is involved in nuclear assembly.
We, and others, have cloned a 95-kD nuclear protein
named HA95/NAKAP95/HAP95 (Orstavik et al., 2000;
Seki et al., 2000; Westberg et al., 2000). HA95 displays
partial homology to AKAP95, a member of the A-kinase
anchoring protein family, but it lacks a protein kinase A
(PKA)–binding domain. HA95 appears in photobleaching
experiments as a stable protein and cofractionates with chro-
matin and a nuclease- and salt-resistant “matrix.” HA95
associates with itself (Orstavik et al., 2000) and interacts
with RNA helicase A (RHA) to enhance expression of a con-
stitutive transport element (CTE) involved in nuclear export
of retroviral RNA (Westberg et al., 2000; Yang et al., 2001).
In vitro nuclear breakdown and reassembly assays combined
with antibody-blocking experiments have shown that HA95
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is involved in NE breakdown and chromatin condensation,
whereas a role in nuclear membrane reassembly is unlikely
(Martins et al., 2000).
Initiation of DNA replication involves the assembly of
prereplication complexes (preRCs) at origins of replication
in G1 (Kelly and Brown, 2000; Bell and Dutta, 2002). Pre-
RCs include the origin recognition complex (ORC), the
minichromosome maintenance (MCM) complex, and the
monomeric Cdc6 protein (Bell and Dutta, 2002). ORC re-
cruits Cdc6 into the preRC in G1, and Cdc6 in turn pro-
motes loading of MCM proteins on chromatin (Bell and
Dutta, 2002). In human cells, Cdc6 levels are relatively sta-
ble during interphase (Williams et al., 1997; Saha et al.,
1998). Nonetheless, a fraction of Cdc6 is exported out of
the nucleus (Coleman et al., 1996) while another remains
associated with chromatin during S and G2 phases (Cover-
ley et al., 2000; Mendez and Stillman, 2000). Proteolysis of
free Cdc6, not assembled into preRCs, has also been re-
ported (Coverley et al., 2000). Thus, after origin firing at
the start of S phase, preRCs are dissociated, ensuring a single
round of replication per cell cycle.
We provide evidence here that HA95 interacts with
LAP2
 
 
 
 via two distinct domains. Blocking the association of
HA95 with LAP2
 
 
 
 does not affect nuclear assembly in vitro.
However, disruption of the association of HA95 with the
NH
 
2
 
-terminal HA95-binding domain of LAP2
 
 
 
 triggers
proteasome-mediated degradation of Cdc6 and inhibits ini-
tiation, but not elongation, of replication. The results sug-
gest an implication of the association of HA95 with LAP2
 
 
 
in regulating the initiation phase of DNA replication.
 
Results
 
HA95 and LAP2
 
 
 
 coprecipitate in interphase
 
HA95 coprecipitates with a protein complex containing
LAP2
 
 
 
 from the transformed human B cell line Bjab in in-
terphase (Martins et al., 2000). We now show that in Bjab
cells, HA95 and LAP2
 
 
 
 coprecipitated in interphase but not
at mitosis, regardless of the precipitating antibody (Fig. 1
A). Immunoblots of the nonprecipitated (S) fractions indi-
cate that in interphase, HA95 coprecipitated all detectable
LAP2
 
 
 
, whereas LAP2
 
 
 
 did not precipitate all HA95 (Fig. 1
A). Immunoprecipitation of an HA95–Myc fusion protein
stably expressed in Bjab cells using an anti-Myc antibody
also coprecipitated LAP2
 
 
 
 in interphase but not at mitosis
(Fig. 1 B). These results suggest a cell cycle–dependent inter-
action of HA95 with LAP2
 
 
 
; however, not all HA95 resides
in a complex with LAP2
 
 
 
.
The strength of interaction between HA95 and LAP2
 
 
 
within the complex was evaluated by a 30-min extraction of
anti-HA95 immune precipitates (HA95-IPs) with 0–1.25 M
NaCl. Fig. 1 C shows that the interaction resisted a
0.75 M NaCl wash but was completely disrupted with 1.25 M
NaCl. High salt resistance of the interaction suggests a strong
association between HA95 and LAP2
 
 
 
, confirming our ear-
lier cross-linking data (Martins et al., 2000).
 
Mapping of the HA95-binding domains of LAP2
 
 
 
To map the domains of LAP2
 
 
 
 involved in the interaction
with HA95, GST–LAP2
 
 
 
 fusion polypeptides were pro-
 
duced (Fig. 2 A) (Furukawa et al., 1995, 1997, 1998).
Binding of each peptide to HA95–Myc was determined in
GST precipitations after incubation of the peptides in a
nuclear extract from Bjab cells expressing HA95–Myc.
Control extracts were incubated with GST or glutathione
beads alone. GST precipitates were immunoblotted using
anti-Myc antibodies. Fig. 2 B shows that LAP2
 
 
 
(1–452),
(1–397), (1–298), (137–373), (137–298), (243–397),
(243–373), (299–397), and (299–373) precipitated HA95–
Myc. In contrast, LAP2
 
 
 
(1–193), (1–85), or (194–298)
did not precipitate HA95–Myc. Thus, a first HA95-bind-
ing domain localizes to amino acids 137–242 of LAP2
 
 
 
and a second domain coincides with the lamin B–binding
domain at residues 299–373. We designated these domains
HA95-NBD (for HA95 NH
 
2
 
-terminal binding domain)
and HA95-CBD (HA95 COOH-terminal binding do-
main), respectively.
The Myc tag itself did not bind GST or LAP2
 
 
 
.
LAP2
 
 
 
(137–373), which binds HA95–Myc, did not copre-
cipitate a stably expressed Myc-tagged p70S6 kinase (Fig. 2
C). Furthermore, anti-Myc antibodies coprecipitated LAP2
 
 
 
(1–397) but not the nonbinding fragment LAP2
 
 
 
(1–193)
from a nuclear extract of Bjab cells expressing HA95–Myc
(unpublished data). Altogether, the results indicate that HA95
interacts with recombinant LAP2
 
 
 
.
Direct association of LA2
 
 
 
 with HA95 was demonstrated
in an overlay assay. HA95-IP proteins were resolved by
Figure 1. HA95 coprecipitates with LAP2  in interphase. 
(A) HA95 or LAP2  was immunoprecipitated (IP) from interphase 
and mitotic Bjab cells. Precipitates (P) and supernatants (S) were 
immunoblotted using anti-LAP2  or anti-HA95 antibodies. (B) Myc-
tagged HA95 was immunoprecipitated from Bjab cells stably 
expressing HA95–Myc using anti-Myc antibodies, and precipitates 
were immunoblotted using indicated antibodies. Control immuno-
precipitations were done with preimmune rabbit IgGs. (C) HA95-IPs 
were extracted with 0, 0.25, 0.5, 0.75, 1.0, or 1.25 M NaCl before 
sedimentation and immunoblotting of pellets and supernatants.T
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SDS-PAGE, blotted, and overlaid with 50 
 
 
 
M of each
GST–LAP2
 
 
 
 fragment. The same GST–LAP2
 
 
 
 peptides
found to precipitate HA95 also bound HA95 in the overlay,
as detected with anti-GST antibodies (Fig. 2 D, top). More-
over, all LAP2
 
 
 
 fragments containing the lamin B–binding
domain (residues 299–373) bound to immunoprecipitated
and immobilized lamin B (Fig. 2 D, bottom). However,
two of the HA95-binding peptides, LAP2
 
 
 
(1–298) and
LAP2
 
 
 
(137–298), did not bind lamin B, confirming the ex-
istence of an HA95-binding domain (HA95-NBD) distinct
from the lamin B–binding region.
To determine whether HA95-binding LAP2
 
 
 
 peptides
would disrupt endogenous HA95–LAP2
 
 
 
 association, dis-
sociation experiments were performed using GST–LAP2
 
 
 
peptides harboring both HA95-binding domains (LAP2
 
 
 
[137–373]) or either HA95-NBD (LAP2
 
 
 
[137–298]) or
HA95-CBD (LAP2
 
 
 
[299–373]). HA95-IPs were incubated
for 1 h with 100 
 
 
 
M GST–LAP2
 
 
 
 peptides, HA95-IPs
were sedimented, and dissociation of LAP2
 
 
 
 from HA95
was monitored by immunoblotting. LAP2
 
 
 
(137–373) com-
pletely dissociated LAP2
 
 
 
 from HA95-IP (Fig. 2 E, lanes
1 and 2), however peptides containing HA95-NBD or
HA95-CBD were ineffective (lanes 3–6). Nevertheless,
two sequential 30-min incubations of HA95-IPs with
LAP2
 
 
 
(137–298) followed by LAP2
 
 
 
(299–373) led to
dissociation of the complex (lanes 7 and 8), and reversing
the order of peptide addition produced similar results
(lanes 9 and 10). We concluded that disruption of both
HA95-binding domains was required for dissociation of
LAP2
 
 
 
 from HA95 in vitro. The data also argue that
LAP2
 
 
 
(137–298) and LAP2
 
 
 
(299–373) peptides are ca-
pable of dissociating HA95 from HA95-NBD and HA95-
CBD, respectively.
 
Inhibition of LAP2
 
 
 
 binding to HA95 does not affect 
nuclear reassembly in vitro
 
To determine whether interaction between HA95 and LAP2
 
 
 
was involved in NE assembly, we assessed the ability of HA95-
binding GST–LAP2
 
 
 
 peptides to compete with LAP2
 
 
 
 for
membrane targeting to chromosomes. Purified HeLa nuclei
were disassembled in mitotic extract. The resulting condensed
chromosomes contained HA95 and BAF, but no A- or B-type
lamins, LAP2
 
 
 
, or lamin B receptor (LBR) (Fig. 3 A). After
preincubation with 10 
 
 
 
M of each GST–LAP2
 
 
 
 peptide,
chromosomes were sedimented and peptide binding was ex-
amined by immunofluorescence using anti-GST antibodies.
All peptides except GST–LAP2
 
 
 
(194–298) bound chromatin
(Fig. 3 B), as anticipated from their ability to bind HA95 (Fig.
2), DNA, or chromatin (see Introduction). Chromosomes
were resuspended in interphase extract (Fig. 3 C, Input
chrom.) under conditions promoting nuclear assembly. Nu-
clear morphology was examined by phase contrast microscopy
and membrane labeling with DiOC
 
6
 
 after 2 h (Fig. 3 C).
Without peptide or with GST alone, 
 
 
 
80% of chromatin
masses supported nuclear reformation. In contrast, LAP2
 
 
 
fragments (1–452), (1–397), (137–373), (243–397), (299–
397), (243–373), and (299–373) inhibited nuclear assembly.
Each of these peptides contained the lamin B–binding do-
main/HA95-CBD. Peptides that do not bind HA95 (nor
lamin B) (LAP2
 
 
 
[1–193], [1–85], and [194–298]) did not
block membrane assembly, neither did LAP2
 
 
 
(1–298) or
(137–298), which both contain HA95-NBD.
To address whether disruption of the of HA95–LAP2
 
 
 
 in-
teraction altered global nuclear organization, localization of
LAP2
 
 
 
, A- and B-type lamins, and BAF was analyzed by im-
munofluorescence in nuclei reconstituted in the presence of
either no peptide, a peptide not binding to HA95 (LAP2
 
 
 
[1–
Figure 2. LAP2  interacts with HA95 
via two distinct domains. (A) GST–LAP2  
deletion peptides. (B) Indicated peptides 
were incubated in nuclear extracts of 
Bjab cells expressing HA95–Myc and 
sedimented by GST precipitation. Binding 
of HA95–Myc to peptides was analyzed 
by immunoblotting using anti-Myc 
antibodies. Control incubations contained 
GST or glutathione beads alone. (C) GST–
LAP2 (137–373) was incubated in a 
nuclear extract of Myc-tagged p70S6 
kinase-expressing cells, and binding (or 
lack thereof) of p70S6 kinase to the 
peptide was detected by GST precipitation 
and immunoblotting. (D) GST–LAP2  
overlays of immunoprecipitated HA95 
or B-type lamins. Peptide binding was 
detected using anti-GST antibodies. 
(E) Peptide-mediated dissociation of 
LAP2  from HA95. HA95-IPs were 
incubated with 100  M GST–LAP2  
peptides, HA95-IPs were sedimented, and 
pellets and supernatants were immuno-
blotted using the indicated antibodies. 
Arrows indicate incubation with 
LAP2 (137–298) followed by addition of 
LAP2 (299–373) (lanes 7 and 8) or vice 
versa (lanes 9 and 10).T
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193]), or peptides containing both HA95-NBD and HA95-
CBD (LAP2 [137–373]), HA95-NBD only (LAP2 [137–
298]), or HA95-CBD only (LAP2 [299–373]). Anti-GST
immunolabeling shows peptide distribution in the resulting
nuclei or chromatin masses (Fig. 3 D). Distribution of
LAP2 , lamins A/C and B, or BAF was not distinctively al-
tered in nuclei reconstituted with HA95-binding or nonbind-
ing LAP2  peptides (Fig. 3 D). LAP2  targeting to chroma-
tin and nuclear assembly of A- and B-type lamins, or lack
thereof, were verified by immunoblotting nuclei or chromatin
purified from the extract (Fig. 3 E). The blots also showed
that levels of chromatin-associated BAF were not significantly
altered by GST–LAP2  fragments (Fig. 3 E). We concluded
that LAP2  fragments containing the lamin B–binding do-
main and HA95-CBD prohibit nuclear reformation. How-
ever, peptides harboring HA95-NBD only are not inhibitory
and do not notably affect the distribution of NE proteins or
BAF in the reassembled nuclei. Thus, we could not attribute
an effect of HA95 binding per se on NE assembly in vitro.
LAP2 (137–298) inhibits initiation of DNA replication 
in intact nuclei in vitro
To determine whether interphase nuclear functions were af-
fected by the HA95–LAP2  association, we monitored the ef-
fect of disrupting the LAP2 –HA95 interaction on DNA rep-
lication in purified G1-phase nuclei. To this end, we adapted
an in vitro replication assay from that of Krude et al. (1997).
Nuclei were isolated from G1-phase HeLa cells. GST–
LAP2  peptides were introduced into the nuclei after mild
treatment with lysolecithin. Lysolecithin was previously
shown not to affect dynamic properties of isolated nuclei in
in vitro nuclear disassembly assays (Collas et al., 1999). Pep-
tides were taken up by  90% of the nuclei, as shown by im-
munofluorescence using anti-GST antibodies (Fig. 4 A;
GST–LAP2 [1–452] is shown). Control and peptide-
loaded nuclei were incubated for 3 h in a concentrated (25–
30 mg/ml) nuclear and cytosolic extract from S-phase HeLa
cells containing [ 
32P]dCTP, dNTPs, GTP, and an ATP-
regenerating system to promote replication. Under these con-
ditions, G1 nuclei loaded with GST–LAP2 (1–452) were
capable of importing an exogenous BSA–nuclear localization
signal conjugate (unpublished data) or the replication factor
Cdc6 (Fig. 4 B). Import was ATP and GTP dependent and
blocked by preincubation of the nuclei with antibodies
against nucleoporins (Fig. 5 B, mAb414). These results indi-
cate that import took place through nuclear pores rather
than passively through a damaged NE, and confirmed a pre-
vious report of physiological import of transcription factors
Figure 3. Disruption of HA95 interaction with LAP2  does not interfere with nuclear assembly in vitro. (A) Purified HeLa nuclei (Nuc) were 
disassembled in mitotic extract, and chromosomes (Chr) were immunoblotted using the indicated antibodies. (B) Indicated GST–LAP2  peptides 
were allowed to bind to chromosomes, and binding was analyzed by immunofluorescence using anti-GST antibodies. Insets, DNA labeled 
with Hoescht 33342. (C) Chromosomes harboring the indicated peptides were incubated in interphase extract under conditions promoting 
nuclear formation. Membrane assembly was examined by DiOC6 labeling and phase contrast microscopy. (D) At the end of incubation, the 
nuclear distribution of GST–LAP2  peptides, LAP2 , A- and B-type lamins, and BAF was examined by immunofluorescence. (E) Nuclei or 
chromatin masses were also sedimented through sucrose, and proteins were immunoblotted using the indicated antibodies. Bars, 10  m.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
B
i
o
l
o
g
y
 A novel nuclear membrane–chromatin interaction | Martins et al. 181
by nuclei purified as previously described (Landsverk et al.,
2002). We also tested whether peptides containing HA95-
NBD or HA95-CBD introduced into G1 nuclei would in-
hibit nuclear import under the conditions described above,
as this would be expected to affect DNA replication. Fig. 4 C
shows that none of the peptides distinctly impaired import
of Cdc6. Notably, import was permitted by the HA95-
NBD–containing peptide LAP2 (137–298) and blocked by
mAb414. Lastly, the nuclear DNA did not undergo any de-
tectable degradation upon incubation of the G1 nuclei in the
extract at 4 C or 37 C, as judged by TUNEL analysis (Fig. 4
C) and DNA agarose gel electrophoresis (Fig. 4 D). These
results indicate that isolated G1 nuclei are functional in im-
port, can be manipulated to introduce peptides, and do not
undergo detectable DNA degradation in S-phase extract,
and that LAP2  fragments containing either HA95-binding
domain do not block nuclear import of Cdc6 in vitro.
Having characterized the nuclei, the effect of GST–
LAP2  peptides on replication was examined. Replication
was assayed by incorporation of [ 
32P]dCTP, DNA electro-
phoresis, and phosphorImaging (Fig. 5 A). Absence of
GST–LAP2  peptide or loading GST alone into G1 nuclei
did not hinder replication. As expected, DNA synthesis was
blocked with 50  M aphidicolin in the extract. However,
LAP2 (1–452) and (1–397) abolished replication and pep-
tides containing HA95-CBD (LAP2 [243–397], [299–
397], [243–373], and [299–373]) impaired replication effi-
ciency by  50%. Furthermore, LAP2 (1–298), (1–193),
(137–373), and (137–298) inhibited replication, whereas
LAP2 (194–298) did not. We also ruled out the possibility
that the DNA replication signal detected in G1 nuclei repre-
sented an elongation phase in already replicating nuclei, be-
cause G1 nuclei incubated in extract from G0-arrested cells
did not replicate (Fig. 5 B).
Initiation of replication requires the cyclin A–Cdk2 com-
plex (Stoeber et al., 1998). Thus, to provide evidence that
DNA synthesis in G1 nuclei was due to true initiation of rep-
lication, we showed that DNA synthesis was inhibited with
10   M of the Cdk2 inhibitor, olomoucine, in the assay
(Stoeber et al., 1998) (Fig. 5 B). Similar results were obtained
with 500  g/ml dimethylaminopurine, a nonspecific protein
kinase inhibitor (unpublished data). Altogether, the results
indicate that peptides containing HA95-CBD partially in-
hibit replication in G1 nuclei. However, those containing
HA95-NDB completely abolish replication. We ruled out an
involvement of the GCL-binding domain of LAP2  (resi-
dues 219–298) in inhibition of replication by fragment 137–
298 because LAP2 (194–298) was not inhibitory.
As described earlier in the nuclear reconstitution experi-
ment, none of the peptides altered the immunofluorescence
labeling pattern of LAP2 , A- and B-type lamins, or BAF in
the G1 nuclei examined (unpublished data; see also below).
In addition, Western blot analysis of the G1 nuclei loaded
with the peptides shows that neither peptide affected BAF
levels (or HA95) in the nuclei (Fig. 5 C). As LAP2 (1–193)
and (137–298) block replication whereas LAP2 (194–298)
and (1–85) allow replication (Fig. 5 D), the data suggest that
region 137–193 of LAP2  is involved in replication initia-
tion without affecting the distribution of NE proteins or the
amount of BAF in the nuclei.
To establish that the LAP2 (137–298) peptide inhibited
semiconservative DNA replication in G1 nuclei, BrdU sub-
stitution and density gradient centrifugation of 
32P-labeled
DNA was performed. G1 nuclei loaded with no peptide,
Figure 4. Characterization of nuclei used 
in the in vitro DNA replication assay. 
(A) Nuclei purified from HeLa cells in G1 
phase were loaded with GST–LAP2 (1–452). 
Peptide uptake was analyzed by immuno-
fluorescence using anti-GST antibodies. 
(B) GST–LAP2 (1–452)-loaded G1 nuclei 
were exposed to an S-phase extract, and 
import of Cdc6 was visualized by immuno-
fluorescence. Note that the G1 nuclei contain 
low detectable levels of Cdc6. (C) Cdc6 
import was also examined in nuclei 
containing the indicated peptides. G1 nuclei 
were also analyzed by (D) TUNEL and (E) 
electrophoresis to monitor DNA degradation 
after exposure to replication extract at 4 C 
or 37 C. Bars, 10  m.T
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GST alone, or LAP2 (137–298) were incubated for 3 h in
S-phase extract containing BrdU and [ 
32P]dCTP to quan-
titate replication. DNA was analyzed by CsCl gradient cen-
trifugation. In control nuclei, the cytosol promoted DNA
synthesis, producing primarily hemisubstituted (heavy-light
[HL]) DNA, indicative of semiconservative replication (Fig.
5 E). In contrast, no peak of hemisubstituted DNA was de-
tected in nuclei loaded with LAP2 (137–298), consistent
with replication inhibition detected by 
32P incorporation.
We concluded that LAP2 (137–298) interfered with semi-
conservative replication in G1 nuclei.
Disrupting LAP2 –HA95 interaction does not affect 
the elongation phase of DNA replication in vitro
We next determined whether the elongation phase of repli-
cation was also affected by LAP2  peptides. Nuclei isolated
from S-phase HeLa cells were loaded with each GST–
LAP2  peptide (Fig. 5 F, left; GST–LAP2 [1–452] is
shown) and incubated in S-phase extract under conditions
promoting replication. Remarkably, all peptides supported
DNA synthesis to the same extent as a control without pep-
tide (Fig. 5 F). In addition, to validate our DNA replication
assay, we showed that DNA synthesis occurred in S-phase
nuclei incubated in extract from G0 cells, reflecting the rep-
licating state of these nuclei (Fig. 5 B). In contrast, G0 nu-
clei did not synthesize DNA in S-phase extract. Note, how-
ever, a faint 
32P label in G0 nuclei in the S-phase extract, due
to a minor proportion of slowly replicating nuclei in the G0
cell population (unpublished data).
HA95 coimmunoprecipitates with the Cdc6 protein 
in G1 phase
Initiation of DNA replication requires the assembly of pre-
RCs at origins of replication in G1. The chromatin-bound
ORC complex recruits Cdc6, which in turn promotes tar-
geting of MCM proteins. HA95 and Cdc6 were found to
coimmunoprecipitate from G1-phase HeLa cells; neverthe-
less, whereas anti-HA95 antibodies precipitated all detect-
Figure 5. LAP2 (137–298) inhibits initiation of DNA replication in G1 nuclei. (A) Peptide-loaded G1 nuclei were incubated in S-phase 
extract containing [ 
32P]dCTP, dNTPs, GTP, and an ATP-regenerating system. [ 
32P]dCTP incorporation was analyzed by phosphorImager 
(cpm/10
5 nuclei). (B) Nuclei isolated from HeLa cells at the indicated cell cycle stages were incubated in extracts from S or G0 cells under 
conditions promoting replication. S-phase extracts also contained 1 mM olomoucine ( Olo) or H2O ( Olo) (right panel). Synthesized DNA 
was analyzed by autoradiography. (C) Relative BAF content of G1 nuclei loaded with the indicated peptides and exposed to S-phase extract 
was examined by immunoblotting. HA95 was also detected as a loading control in the gel. (D) Summary of GST–LAP2  peptides harboring 
HA95-NBD supporting ( ) or inhibiting ( ) replication in G1 nuclei. (E) BrdU density substitution experiment. G1 nuclei containing either 
no peptide (circles), GST alone (triangles), or GST–LAP2 (137–298) (squares) were allowed to replicate in S-phase extract containing BrdU 
and [ 
32P]dCTP. Substituted DNA was separated by centrifugation in CsCl gradients. cpm of each fraction was plotted against fractions of 
equal densities. HL indicates density of heavy-light replicated DNA. (F) Nuclei from S-phase HeLa cells were loaded with GST–LAP2  
peptides and peptide uptake was analyzed as in Fig. 4 A (GST–LAP2 [1–452] is shown). Peptide-loaded nuclei were incubated in S-phase 
extract and incorporation of [ 
32P]dCTP was measured by phosphorImager (cpm/10
5 nuclei). Bar, 10  M.T
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able Cdc6, a substantial fraction of HA95 did not associate
with the Cdc6 immune precipitate (Fig. 6 A). In S phase
however, Cdc6 and HA95 did not coprecipitate (Fig. 6 A),
despite the reported persistence of a fraction of Cdc6 on
chromatin beyond G1 (Mendez and Stillman, 2000).
Disruption of the interaction between HA95 and LAP2  
via HA95-NBD in G1 induces proteolysis of Cdc6
The role of Cdc6 on preRC assembly led us to investigate the
fate of Cdc6 in G1 nuclei after disruption of the HA95–
LAP2  association via HA95-NBD or HA95-CBD. GST–
LAP2  peptides were introduced into purified G1 HeLa nu-
clei and nuclei were incubated in nuclear isolation buffer for
1 h. Immunoblotting analyses of the nuclei show that nuclei
loaded with GST alone or with LAP2 (299–373) contained
Cdc6 (Fig. 6 B, lanes 1–3). However, nuclei loaded with
LAP2 (137–298) or LAP2 (1–452) harbored no detectable
Cdc6 (lanes 4 and 5). Additionally, blots of the whole incu-
bation mix (nuclei and buffer) revealed no Cdc6 either, indi-
cating that Cdc6 was degraded under these conditions (lane
9; see below). Note that p53 was also degraded in nuclei con-
taining peptides harboring HA95-NBD, however, Orc2, a
component of the preRC, was not affected (lanes 4 and 5).
The ORC large subunit has recently been shown to be de-
graded by ubiquitin-mediated proteolysis in human cells
(Mendez et al., 2002). Thus degradation of Cdc6 by the 25S
proteasome was examined. Inhibition of the proteasome by in-
cubation of nuclei containing LAP2 (137–298) with 25  M
of the proteasome inhibitors LLnL or  -lactone during peptide
loading and incubation in buffer prevented degradation of
Cdc6 (Fig. 6 B, lanes 6 and 7). However, the calpain inhibitor
LLM, used as a control, did not block Cdc6 proteolysis (lane
8). Inhibition of degradation of p53, a known substrate of
ubiquitin-mediated proteolysis, with LLnL or  -lactone con-
firmed the efficacy of the inhibitors (Fig. 6 B). Introduction of
LAP2 (137–298) in S-phase nuclei did not elicit degradation
of Cdc6 (or p53 or Orc2; unpublished data). These results
suggest that dissociation of HA95 from HA95-NBD in G1-
but not S-phase nuclei triggers degradation of Cdc6 by the
proteasome. Because p53 is also proteolyzed by LAP2 (137–
298), the data also suggest that the peptide promotes degrada-
tion of a subset of nuclear proteins.
Figure 6. Dissociation of HA95 from 
HA95-NBD in G1 elicits degradation of 
Cdc6. (A) HA95 (top three panels) or 
Cdc6 (bottom three panels) was immuno-
precipitated from G1- or S-phase HeLa 
cells, and immune precipitates (P) and 
supernatants (S) were immunoblotted 
using either precipitating antibody. 
(B) Nuclei from G1-phase cells (lane 1) 
or G1 nuclei loaded with the indicated 
GST–LAP2  peptides (lanes 2–5) and 
incubated in nuclear isolation buffer 
for 1 h were immunoblotted using the 
indicated antibodies. In lanes 6–8, G1 
nuclei loaded with LAP2 (137–298) 
were incubated in buffer for 1 h together 
with 25  M  -lactone, LLnL, or LLM. In 
lane 9, whole samples (WS; nuclei   buffer) were immunoblotted. (C) G1 nuclei were loaded with GST–LAP2 (137–298) or GST–LAP2 (299–373) 
in the presence of no inhibitor ( ),  -lactone, LLnL, or LLM. Nuclei were allowed to replicate in S-phase extract containing [ 
32P]dCTP, and 
synthesized DNA was analyzed by autoradiography.
Figure 7. Nuclear injection of GST–LAP2 (137–298) 
in G1 does not alter distribution of NE proteins or 
BAF. Nuclei of G1 HeLa cells were injected with 
5 ng of the indicated GST–LAP2  peptide or GST 
alone, cultured for 2–3 h, and analyzed by immuno-
fluorescence using anti-GST, LAP2 , lamin B (goat 
polyclonal), or BAF antibodies. Arrows point to 
noninjected cells. Bar, 10  m.T
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As G1 nuclei containing LAP2 (137–298) do not repli-
cate DNA in S-phase extract, we determined whether pro-
teasome inhibitors would rescue S-phase entry of these nu-
clei. G1 nuclei were loaded with LAP2 (137–298) in the
presence of LLnL or  -lactone and incubated for 3 h in
S-phase extract containing [ 
32P]dCTP under conditions
promoting replication. Fig. 6 C shows that LLnL and  -lac-
tone relieved the inhibition of DNA replication imposed by
LAP2 (137–298). The calpain inhibitor LLM, however,
had no effect and, as expected, LLnL or  -lactone did not
affect replication of LAP2 (299–373)-loaded G1 nuclei
(Fig. 6 C). Therefore, inhibition of the proteasome enables
entry of the G1 nuclei into a replication phase.
Injection of LAP2 (137–298) into G1 nuclei inhibits 
entry into S phase in vivo
The significance of HA95 interaction with HA95-NBD or
HA95-CBD was further investigated in vivo by injections of
 5 nM GST–LAP2  peptides into the nuclei of HeLa cells
in early G1 (2 h after release from mitotic arrest). Injections
were verified by nuclear retention of a 150-kD FITC–dextran
(see below and Fig. 8 A).
We first assessed whether the distribution of INM and
lamina proteins was altered in the injected nuclei. As seen
earlier in in vitro–reconstituted nuclei, GST–LAP2  pep-
tides were detected throughout the nucleus for the most
part, with a propensity of the anti-GST antibody to decorate
the nuclear periphery more strongly (Fig. 7, GST). This,
however, was not specific for the peptide injected (Fig. 7,
bottom three rows). Immunofluorescence analysis of pep-
tide- and mock (buffer)-injected cells indicated that LAP2 
and B-type lamins remained localized at the NE 2–3 h after
injection with either peptide (Fig. 7). Similar results were
obtained for LBR, emerin, and A-type lamins (unpublished
data). Additionally, no alteration in the localization of BAF
in peptide-injected and control cells was detected (Fig. 7).
BAF remained distributed throughout the nucleoplasm with
an enrichment around the periphery. Thus, we could not at-
tribute a noticeable effect of intranuclear peptide injection
in G1 on overall nuclear architecture.
To examine the effect of peptide injection in G1 on DNA
replication, injected G1-phase cells were cultured with 10
 M BrdU for 10 h and DNA synthesis was monitored using
anti-BrdU antibodies. Fig. 8 (A and B) shows that 95% of
mock-injected cells underwent DNA synthesis, which was
inhibited by 50  M aphidicolin. Likewise, cells injected
with LAP2 (1–85) or GST alone replicated DNA. How-
ever, LAP2 (137–298) abolished DNA synthesis in 90% of
the cells, whereas LAP2 (299–373) had no effect. Injection
of LAP2 (137–298) in S-phase nuclei was not inhibitory
(unpublished data), indicating that once DNA synthesis is
initiated, disruption of the LAP2 –HA95 interaction via
HA95-NBD has no effect.
Additional immunofluorescence analysis of injected G1
HeLa cells indicated that Cdc6 was undetectable in LAP2 
(137–298)-injected cells, whereas intranuclear labeling was
evident in noninjected cells (Fig. 8 C, arrow) or in cells
injected with GST alone or LAP2 (299–373) (Fig. 8 C).
Note that Orc2 was not degraded in LAP2 (137–298)-
injected cells, as shown by intranuclear immunolabeling
(Fig. 8 C). The results indicate that, as shown biochemically
in vitro, LAP2 (137–298) inhibits S-phase entry in vivo.
Inhibition correlates with the degradation of Cdc6, but is
not due to a displacement of NE proteins or a change in
BAF distribution during G1.
Discussion
Anchoring of the INM to chromatin
This study provides evidence for a novel direct interaction
of the NE with the genome, via the INM protein LAP2 
and the chromatin- and nuclear matrix–associated protein
HA95. The nucleoplasmic 410 amino acids of LAP2  are
Figure 8. Nuclear injection of GST–LAP2 (137–298) in G1 
inhibits replication. Nuclei of G1 HeLa cells were injected with 
5 ng of the indicated GST–LAP2  peptide or GST alone together 
with a 150-kD FITC–dextran to visualize injections, and cells were 
cultured for 9–10 h with BrdU. Mock (buffer)-injected cells were 
also cultured with BrdU and 50  M aphidicolin. BrdU incorporation 
was detected using TRITC-conjugated anti-BrdU antibodies. DNA 
was labeled with Hoechst 33342. (B) Percentages of cells labeled 
with BrdU 9–10 h after peptide injection (n   45–50/treatment in 
two replicates). (C) Immunofluorescence analysis of Cdc6 and 
Orc2p in G1 cells injected as in A. Cells were fixed 2 h after peptide 
injection. Arrows point to noninjected cells. Bars, 10  m.T
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prompt to interactions with multiple intranuclear ligands
(Fig. 9). The first 50 residues are common to all LAP2 pro-
teins and bind DNA (Cai et al., 2001), in consistency with
the chromatin-binding property of this region, which causes
post-mitotic association of LAP2  with chromosomes (Vl-
cek et al., 1999). LAP2 proteins also bind the DNA-bridg-
ing protein BAF through residues 67–137 (Furukawa, 1999;
Shumaker et al., 2001), which include most of the LEM do-
main (Fig. 9). The significance of this interaction in inter-
phase remains unclear, although a role in chromatin decon-
densation and nuclear expansion in vitro has been proposed
(Segura-Totten et al., 2002). LAP2  also binds GCL, a
transcription regulator that interacts with components of the
E2F transcription machinery (Nili et al., 2001). LAP2  is
capable of reducing the transcription activity of the E2F
complex alone or with GCL (Nili et al., 2001), suggesting
an involvement of the NE in transcription regulation. It will
be interesting to determine whether mutations in NE pro-
teins that cause disease (Vigouroux and Bonne, 2002) also
lead to defects in transcription regulation in affected tissues.
We now show that LAP2  also directly interacts with the
chromatin-associated protein HA95 via two HA95-binding
domains that are distinct from the chromosome-binding re-
gion. The NH2-terminal domain (HA95-NBD) localizes
within amino acids 137–242, while the COOH-terminal
domain (HA95-CBD) is restricted to residues 299–373
(Fig. 9). HA95-NBD partially overlaps with the 187 NH2-
terminal amino acids common to all LAP2 proteins, thus
HA95-NBD may not be restricted to NE-associated LAP2 
and may also exist in intranuclear LAP2 proteins. HA95-
CBD coincides with the lamin B–binding domain of
LAP2  and is unique to LAP2 , nevertheless LAP2  binds
HA95 independently of lamin B in vitro. The functional
implications of each HA95-binding domain of LAP2  are
important, as disruption of only one or the other has distinct
effects on NE assembly or DNA replication (see below). As
the binding domains to each ligand are distinct, interaction
of LAP2  with either domain may not be exclusive, and it is
tempting to speculate that a single protein of the INM may
regulate chromatin function at multiple levels in interphase.
Interaction between HA95 and LAP2  is dispensable 
for nuclear membrane assembly
We previously reported that anti-HA95 antibody-mediated
blocking of HA95 function on condensed chromosomes had
no inhibitory effect on nuclear membrane assembly in vitro
(Martins et al., 2000). This suggested that HA95 may not be
involved in membrane targeting to chromatin. Our results
indicate that any LAP2  fragment that can bind lamin B in-
hibits nuclear assembly, however peptides that bind HA95,
but not lamin B, fail to inhibit assembly. Thus, competition
for LAP2  binding to HA95 has no detectable effect on nu-
clear formation. Although our results show that the lamin
B–binding domain of LAP2  is involved in NE formation
(Yang et al., 1997; Gant et al., 1999), they document a lack
of effect of HA95 binding activity on nuclear assembly.
Role of association of HA95 with the NH2-terminal 
HA95-binding domain of LAP2  in DNA replication
Our results suggest that the HA95–LAP2  interaction via
HA95-NBD may represent an additional form of control for
replication initiation, at least in transformed cells. We ruled
out the possibility that disruption of the HA95–LAP2  in-
teraction upon intranuclear introduction of LAP2  frag-
ments affected overall nuclear organization, which in itself
might compromise DNA replication (Gant et al., 1999;
Moir et al., 2000). Notably, the localization of endogenous
LAP2 , A- and B-type lamins, and BAF does not seem to be
perturbed by disruption of the interaction of HA95 with
HA95-NBD upon nuclear reassembly in vitro, in isolated
G1 nuclei, or in G1-phase nuclei in vivo. Additionally, BAF
levels remain unaffected in G1 nuclei, arguing that defects in
replication induced by LAP2  disruptor peptides do not re-
sult from changes in BAF protein levels (Segura-Totten et
al., 2002). The HA95-NBD of LAP2( ) partially overlaps
with the LEM domain, which interacts with BAF. BAF dis-
tribution and levels are not altered by LAP2  peptides con-
taining HA95-NBD, and regions nonoverlapping with the
HA95-binding domain were sufficient for BAF binding in
yeast two-hybrid assays (Furukawa, 1999). Nonetheless,
whether manipulating the association of HA95 with LAP2 
interferes with binding of LAP2 proteins to BAF remains to
be examined (Shumaker et al., 2001).
How does the HA95–LAP2  interaction affect DNA rep-
lication? First, we should emphasize that the domain of
HA95-NBD involved in replication (residues 137–193; Fig.
9) is almost entirely included in the 187 amino acids
(1–187) common to all LAP2 proteins. Thus, the HA95–
LAP2 interaction is probably not restricted to the NE. We
propose a hypothesis whereby interaction of HA95 with the
NH2-terminal domain of LAP2 proteins and with compo-
nents of the preRC brings components of the preRC to rep-
lication origins, maintains integrity of the preRC, and/or
protects preRC components from degradation. It is conceiv-
able that destabilizing the HA95–LAP2  interaction in G1 may
displace preRC components, triggering their proteasome-medi-
ated degradation and, as a result, blocking replication initia-
tion. These alternatives are compatible with the distribution
of preRCs throughout the genome and the intranuclear lo-
calization of LAP2 , a nonmembrane-bound LAP2 isoform
(Vlcek et al., 1999). Disruption of the interaction specifi-
cally abolishes S-phase entry but has no effect on the elonga-
tion phase of replication. Furthermore, HA95 and Cdc6
coimmunoprecipitate in G1 but not S phase, suggesting that
Figure 9. Functional domains of 
LAP2 . Identified functional regions of 
LAP2  (LEM and transmembrane [TM]) 
and domains binding to indicated ligands 
are shown. Numbers refer to amino acid 
positions. See text for references to 
binding domains.T
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HA95 (in)directly interacts with the preRC. The lack of in-
teraction of HA95 with Cdc6 in S phase is consistent with
nuclear export or degradation of a fraction of Cdc6 in mam-
malian cells (Saha et al., 1998; Coverley et al., 2000) and
with disassembly of the preRC.
Disruption of HA95 interaction with HA95-NBD in G1
triggers proteasome-mediated degradation of Cdc6 (and
p53), whereas proteasome inhibitors block LAP2 (137–
298)-induced proteolysis and rescue the replication inhibi-
tory effect of the LAP2  peptide in G1 nuclei. Yet, the
inhibitors obviously did not rescue the LAP2 –HA95 inter-
action, indicating that this association is dispensable for rep-
lication. It is likely that the LAP2 (137–298) peptide causes
degradation of a class of nuclear proteins, because p53 reacts
similarly to Cdc6. This could result from a pleiotropic effect
of the peptide, perhaps disturbing other proteins that inter-
act through a similar domain. In any event, inhibition of
DNA synthesis by LAP2 (137–298) may be indirect, for
example by activating a checkpoint pathway. This specula-
tive hypothesis remains to be tested.
Our results extend the notion that the NE contributes to
regulating replication. In Xenopus, disruption of lamina or-
ganization alters the distribution of replication factors and
inhibits the elongation phase of DNA synthesis (Moir et al.,
2000). Thus, replication may be regulated at several levels by
nuclear lamins and nuclear membrane–chromatin interac-
tions, in addition to interactions between chromatin-associ-
ated proteins.
Multiple functions of HA95 dictated by its interaction 
with multiple ligands
By interacting with several intranuclear ligands, HA95
emerges as a multifunctional molecule. In addition to its in-
volvement in replication, HA95 binds RHA (Westberg et
al., 2000), suggestive of a role in transcription regulation.
RHA binds to a CTE involved in nuclear export of un-
spliced viral RNA, and association of HA95 with RHA en-
hances CTE-mediated gene expression and promotes nu-
clear export of unspliced mRNA (Yang et al., 2001). By
binding to LAP2 , HA95 may favor viral RNA export by
tethering it near the NE.
HA95 also interacts with the catalytic subunit of PKA
within the nucleus and localizes the catalytic subunit to sites
where it can modulate transcription from specific promoters
(Han et al., 2002). Thus, HA95 may act as a targeting mole-
cule for the PKA catalytic subunit in the nucleus. Along this
line, it is tempting to speculate that HA95–LAP2 , or
HA95–LAP2, interactions may promote targeting or stabiliza-
tion of signaling molecules in the vicinity of transcription sites
and at origins of replication at discrete stages of the cell cycle.
Materials and methods
Antibodies and peptides
Anti-Myc antibodies were from Invitrogen. Anti-GST, anti-Cdc6 (H-304
and clone 180.2), anti-Orc2, goat anti–lamin B antibodies, and anti-p53
antibodies were from Santa Cruz Biotechnology, Inc. Anti-BrdU antibodies
were from Sigma-Aldrich. Affinity-purified polyclonal antibodies against
LBR, LAP2 , A- and B-type lamins (gifts from J.-C. Courvalin, Institut J.
Monod, Paris, France), BAF (a gift from K. Wilson, Johns Hopkins Univer-
sity School of Medicine, Baltimore, MD), and HA95 were described else-
where (Buendia and Courvalin, 1997; Orstavik et al., 2000; Haraguchi et
al., 2001). LLnL, LLM, and  -lactone were from Calbiochem. GST–LAP2 
peptides were expressed as previously described (Furukawa et al., 1995,
1997, 1998).
Cells and nuclei
Bjab cells were grown in RPMI 1640/10% FCS (GIBCO BRL) (Orstavik et
al., 2000). HeLa cells were cultured in EMEM/10% FCS (GIBCO BRL).
HeLa cells were synchronized in M phase with 1  M nocodazole for
18 h. To allow cell cycle reentry, cells were plated at 2.5   10
6 cells in
162-cm
2 flasks. G1- and S-phase cells were harvested (or microinjected) 2
and 12 h, respectively, after release from mitotic arrest. Cells were ar-
rested in G0 by a 5-d culture under confluent conditions without serum.
Nuclei were isolated from Bjab cells and from G0-, G1-, or S-phase HeLa
cells by Dounce homogenization (Martins et al., 2000). For nuclear reas-
sembly assays, nuclei were isolated from confluent HeLa cells and used
fresh of frozen/thawed (Steen et al., 2000). Freshly isolated nuclei were
used in replication assays.
Microinjection and BrdU incorporation
HeLa cells released from M-phase arrest were seeded on coverslips.
Within 2 h, nuclei were microinjected with 25 pl PBS containing 10  g/ml
150-kD FITC–dextran to visualize injections, and  5 nM indicated GST–
LAP2  peptide. Cells were cultured in EMEM/10% FCS for up to 10 h with-
out or with 100  M BrdU and processed for immunofluorescence or BrdU
incorporation analysis. S-phase cells were injected 10–12 h after release
from M-phase arrest. Approximately 50 cells were injected per treatment
in two to three replicates. To detect BrdU incorporation, cells were fixed
with methanol for 5 min, blocked, and overlaid with anti-BrdU antibodies
(1:200 dilution) and TRITC-conjugated anti-BrdU antibodies.
Immunological procedures
Immunoblotting analysis was performed as previously described (Martins
et al., 2000) using antibodies against HA95 (1:250 dilution), Myc
(1:1,000), GST (1:1,000), B-type lamins (1:1,000), lamin A/C (1:500),
LAP2  (1:500), LBR (1:500), BAF (1:500), p53 (1:500), Cdc6 (1:500), and
Orc2 (1:500). For immunoprecipitations, cells or nuclei were sonicated in
IP buffer (10 mM Hepes, pH 7.5, 10 mM KCl, 2 mM EDTA, 1% Triton
X-100, 1 mM DTT, and protease inhibitors) and lysates were centrifuged
at 15,000 g for 15 min. Immunoprecipitations were performed from the
supernatants with relevant antibodies (1:50 dilutions) as described earlier
(Martins et al., 2000).
GST precipitation
Nuclei isolated from Bjab cells (10
9 nuclei/ml) were sonicated in GST pre-
cipitation buffer (300 mM KCl, 20 mM Hepes, pH 7.6, 0.1% Triton X-100,
1 mM DTT, 5 mM benzamidine, and protease inhibitors) and the lysate
was centrifuged at 10,000 g. The supernatant (nuclear extract) was incu-
bated with specified GST–LAP2  peptides (1 or 5  g/ l) overnight at 4 C
with rotation. GST precipitations were performed using glutathione beads
coated with 10 mg/ml BSA and pellets were washed in GST precipitation
buffer. Proteins were eluted in SDS sample buffer.
Overlay assays
HA95-IPs proteins resolved by 10% SDS-PAGE were blotted onto nitrocel-
lulose, blocked with 5% milk in Tris-buffered saline/0.01% Tween 20
(TBST) for 1 h, washed in TBST, and overlaid with 10  M GST–LAP2 
peptides for 2 h in TBST. Membranes were washed in TBST and peptide
binding was detected using anti-GST antibodies and peroxidase-conju-
gated secondary antibodies.
Nuclear reconstitution assay
Condensed, membrane-free chromatin masses were prepared from HeLa
nuclei disassembled in mitotic extract (Martins et al., 2000). After sedi-
mentation through 1 M sucrose, chromosomes were resuspended in pep-
tide-binding buffer (100 mM NaCl, 2 mM MgCl2, 2 mM CaCl2, 20 mM
Hepes, pH 7.5, 1 mM DTT, and protease inhibitors) containing 5  M of in-
dicated GST–LAP2  peptides.
After 1 h at room temperature, chromosomes were sedimented,
washed, and either immunologically analyzed or resuspended in nuclear
reassembly extract. In this case, chromosomes (2  l) were resuspended in
40  l of an interphase HeLa cell 200,000 g cytosolic extract at 5,000 chro-
matin masses/ l, containing 4  l mitotic membranes, an ATP-regenerating
system (1.2  l), and 100  M GTP (0.4  l) (Steen et al., 2000). After 2 h at
30 C, nuclear assembly was examined by phase contrast microscopy,T
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membrane staining with 10  g/ml DiOC6, or by immunofluorescence. Nu-
clei or chromatin masses were also sedimented through 1 M sucrose,
washed, and solubilized in SDS sample buffer.
Loading of nuclei with GST–LAP2  peptides
Peptide loading into isolated HeLa nuclei was performed as described ear-
lier (Collas et al., 1999). In brief, nuclei were mildly permeabilized with ly-
solecithin and incubated for 1 h with indicated GST–LAP2  peptides (100
 M) or GST alone. Nuclei were washed by sedimentation through 1 M su-
crose and held on ice until use. Lysolecithin-treated nuclei were capable
of active protein import in vitro (see Results).
In vitro replication and quantification of DNA synthesis
Replication was assayed by incorporation of [ 
32P]dCTP into newly syn-
thesized DNA. Isolated G0-, G1-, or S-phase nuclei (preloaded with GST–
LAP2  peptides, as indicated) were incubated for 3 h at 5,000 nuclei/ l in
40  l of S-phase extract (unless indicated otherwise) containing the ATP-
regenerating system, 100  M GTP, a buffered mix of dNTPs (40 mM
Hepes, pH 7.8, 7 mM MgCl2, 0.1 mM each of dATP, dGTP, dTTP, and
dCTP; 2  l) and 1  l [ 
32P]dCTP (3,000 Ci/mmol; Amersham Biosciences).
Concentrated S-phase whole cell extracts were prepared from S-phase
HeLa cells collected 15 h after release from mitotic arrest. Cells were lysed
by Dounce homogenization in cell lysis buffer (Martins et al., 2000), and
then briefly sonicated on ice to lyse nuclei and release soluble nuclear
components. The lysate was sedimented at 15,000 g for 15 min and then
at 200,000 g for 2 h, both at 4 C. Protein concentration of the extract was
25–30 mg/ml.
At the end of incubation in extract, samples were mixed with 1 volume
of 20 mM Tris (pH 7.5) and 1 mg/ml proteinase K and digested for 2 h at
37 C. Samples were mixed by pipetting and 5- l aliquots were electro-
phoresed through 0.8% agarose. Gel loading was assessed by ethidium
bromide staining. Samples contained equal numbers of nuclei and sedi-
mentation steps were eliminated to avoid loss of nuclei (Gant et al., 1999).
Signals were quantified by phosphorImaging or by autoradiography.
BrdU density substitution
Density substitutions were done as previously described (Gant et al., 1999)
in reactions consisting of isolated G1 nuclei in S-phase extract containing
[ 
32P]dCTP and 0.5 mM BrdU. Samples were digested with proteinase K
and DNA was extracted with phenol–chloroform then chloroform, ethanol
precipitated, and dissolved in 100  l Tris-EDTA buffer. Samples were
mixed with 12 ml of 1.75 g/ml CsCl and centrifuged for 45 h at 60,000 g.
40 fractions were collected, an aliquot was counted by liquid scintillation,
and the refractive index of each fraction was measured (Gant et al., 1999).
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